Adenovirus Producer Cell Lines Reducing RCA Contamination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing replication-defective adenoviruses face challenges such as contamination with replication-competent adenovirus and toxicity associated with high levels of E1A protein expression, leading to inefficient production yields and potential immune responses.
Innovation Solution
Development of new cell lines that incorporate helper adenovirus nucleic acid sequences providing viral functions for recombinant adenovirus replication without being replicated or assembled into viral particles, specifically encoding E1A proteins defective in binding to p300 and Rb protein family members, and including E1B, E2, and E4 proteins to reduce toxicity and contamination risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If E1A and E1B genes are used for complementation of E1-deficient adenoviruses, then high levels of viral replication are achieved, but toxicity and apoptosis are induced
Solution Approach 1:
The E1B gene is divided into two separate expression cassettes: one for E1B-19K protein and another for E1B-55K protein. This segmentation allows independent control of each protein's expression levels, enabling optimization to reduce toxicity while maintaining viral replication efficiency.
Solution Approach 2:
The invention changes the expression parameters by using different promoters (CMV for E1B-19K, RSV for E1B-55K) and adjusting copy numbers of expression cassettes to control protein expression levels. This parameter optimization reduces harmful effects while maintaining productivity.
2Productivity
If 293 cells are used for production, then acceptable levels of rAd vectors are produced, but RCA contamination occurs through homologous recombination
Solution Approach 1:
The invention removes the problematic E1A gene from the cell line genome while retaining E1B expression. This extraction eliminates the source of homologous recombination that generates RCA, while still providing necessary E1B complementation for rAd vector production.
Solution Approach 2:
The cell line uses integrated expression cassettes that copy necessary viral functions (E1B proteins) without containing complete adenovirus genomes. This copying approach provides complementation capability while avoiding the formation of replication-competent adenovirus through recombination.
3Reliability
If PER.C6 cells are used to eliminate RCA, then homologous recombination is reduced, but atypical RCA can still form with non-matched vectors
Solution Approach 1:
The cell line is designed to provide universal complementation functions through E1B proteins that work with multiple different adenovirus serotypes and vector configurations. The E1B-19K and E1B-55K proteins perform essential functions that are broadly applicable across different adenoviral systems.
4Productivity
If high levels of E1A protein are expressed, then viral replication is enhanced, but cell survival decreases due to apoptosis
Solution Approach 1:
The invention uses the E1B-19K protein, which specifically counteracts E1A-induced apoptosis, to convert the harmful effect of E1A expression into a benefit. By providing this protective function, the cell line can tolerate high levels of E1A expression needed for viral replication while maintaining cell survival.
Data Source
AI summary
The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus (“RCA”).